Skip to main content

Comics About Patents (A Work In Progress)

Back in January and February of 2018, I spent some time creating two four-panel comics about the process of 1) obtaining patent protection, and 2) monetizing those patent rights by licensing them. I drew the comics to serve as an illustration of concepts that I often find myself explaining to others in the course of my work.

I've already shared these comics through Twitter and Facebook (click on either of link to see more of the creative process!). However, I thought I'd share them with my blog's readership as well. Please enjoy! I'm really hoping to reignite this project at some point in the future and create more episodes.

(Click on the images below to enlarge)


Episode 1:

Episode 2:


- Isamu Hartman

Comments

Post a Comment

Popular posts from this blog

Corporate Venture Capital at the Top 10 Pharma/Biotech Companies

Today I'm taking a step outside of Texas and looking at the world. Many large pharmaceutical and biotech firms maintain venture capital operations through which they invest in early-stage biomedical companies. I wanted to get a sense of what these biopharma corporate venture capital (CVC) funds are up to. Which companies have CVC funds? How active are they? What are their goals? What are they investing in? Background: general and sector-specific trends in venture capital In 2014 venture capital funding in the U.S. hit its highest annual mark since 2001, as investors participated in $47.3 billion across 3,617 deals . Within this trend Life Sciences was the second largest sector (behind only the Media and Entertainment sector) for 2014 in dollar terms with $8.6 billion invested in 789 deals, the highest level since 2007 . Corporate venture funding has followed similar trends:  2014 marked the strongest year for CVC activity since 2000 with $5.4 billion invested in U.S.-based co
Post a Comment
Read more

Developing Software: What Should Academic Researchers Keep in Mind? (Part 2)

In Part 1   of this essay, I discussed three learning points I'd gained from my encounters with faculty-developed software in my work as a technology transfer officer at an academic medical research institution. Those points were as follows:  Patents aren't a necessary prerequisite for commercializing software Be deliberate in your use of third-party code If you are going to release your source code publicly, consider doing it under a restrictive open source license When I finished writing it, I knew I had more to say on the topic. You can read Part 1 here . Below is my continuation. 4 - Figuring out the ‘thing’ that’s going to be licensed An important part of handing off a software-based technology from university to private industry is to first figure out exactly what is being handed off. This can be tricky! I’ve discovered that software, as a commercial asset, can take many forms. The licensing professional can bring a lot of clarity to the negotiations by making sure both t
Post a Comment
Read more